Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.4 USD | +3.03% | +12.08% | +46.90% |
05-03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
05-02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.90% | 2.29B | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Kymera Therapeutics : Chief Scientific Officer Chesworth to Depart Next Month -- Shares Drop in Late Hours Trading